fbpx
我们正在寻找中国人参与临床研究
News
AKL & HAM - 0800 788 3437
CHC & WLG - 0800 862 278

Important Information

Please note, we need you to ….
  • Read the important documents for this study
  • If you are interested, look at the dates that this study is being run (cohort visit planners) and  reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
  • We will ring you to check your suitability and provide further information about the study
  • We will make you a screening appointment at NZCR Auckland. You will need to attend at the scheduled time if you wish to take part in the study

Study Information

Hepatitis B virus (HBV) infection is associated with increased risks for chronic liver inflammation, a condition known as Chronic Hepatitis B (CHB). CHB is a global condition that can result in severe liver disease, liver cancer, or even death. Current treatments for CHB can suppress the infection and disease in many patients, however, these treatments rarely cure the virus and therefore need to be taken as life-long therapy. Very few patients have any lasting benefit if they stop taking the current standard of care therapy.

GS-2829 and GS-6779 are viral vector vaccines. Viral vector vaccines use a modified, harmless version of a virus (the vector) that contains instructions for making a protein that will be recognised by the immune system as foreign. In the case of the GS-2829 and GS-6779 vaccines, the viral vector enters the cells and expresses HBV proteins, causing the immune system to attack any HBV-infected cells.

GS-2829 and GS-6779 cannot reproduce and cannot cause HBV infection or any other viral infections. The vaccine cannot alter a person’s DNA (genetic material).

Ultimately, GS-2829 and GS-6779 will be used to treat CHB by clearing the virus from the body, with the hope of providing a functional cure for CHB.

The purpose of this study is to:

  • Evaluate how safe and well tolerated multiple doses of GS-2829 and GS-6779 are in healthy participants (Part 1a) and in participants with CHB (Part 1b).
  • Measure the body’s response to a single and multiple doses of GS-2829 and/or GS-6779 in healthy participants (Part 1a) and in participants with CHB (Part 1b).
  • Assess the body’s immune response to GS-2829 and/or GS-6779.

Study Candidates

  • Healthy males and females
  • Aged 18 – 60 years
  • BMI equal to or less than 32 kg/m2
  • No current use of any medication.

What is Involved?

Cohort 4:

  • Study Visits: 13 visits and 8 phone calls
    (0 inpatient stay, 4 of 13  visits will be full day 8-10 hours long)
  • Reimbursement update: $5,250 total (less tax), in 2-payments

Important Documents

Important documents to download and read

Please read through the documents thoroughly and check that the dates work for you.

Pre-screening Form

Personal details

Please provide your name, email and phone number so we can contact you

Medical questions

Have you had any covid symptoms in the last two weeks or been in isolation?
Have you previously participated in a study with NZCR or any other organisation? Give details or leave blank if no
This study requires the use of contraception during the study. If you are in a hetereosexual relationship both partners must agree to use contraception (condoms for males | IUD, birth control or another approved form for females). Is this something you would be okay with?
Have you received blood or plasma in the last few months? If yes please provide details
Any history or current autoimmune disorders? Are you being treated with any immunosuppressive medication? - For e.g., psoriasis, rheumatoid arthritis, Crohn’s disease, or ulcerative colitis etc
Are you pre-diabetic or do you have any history of diabetes?
Any history of abnormal liver or kidney conditions?
Do you have any significant heart disease of heart related conditions?
Do you have any history of allergies, asthma, hay fever, food allergies etc that you are aware of?
Any significant history of Acid reflux or peptic ulcers?
Do you have any history of clinically significant acute systemic infection and/or antibiotic treatment within 28 days?
Do you have any history of medical conditions relating to:(Required)
If you have none, please select the last option.
Have you taken any prescription, vitamins, supplements, pharmacy medication or over the counter medications in the last 28 days? Please include any Vaccines in the last 3 months
Have you looked at the study dates and are okay to come in those days? Indicate which group/s you are available for. This means having flexibility for more than one group increases your chances of being accepted into a group.
Pre-screening form policy(Required)
I understand that by submitting this form, NZCR will use the information for pre-screening purposes for this study. This information may be recorded on your profile to allow us to improve our process when screening you for a future study. All information provided is confidential. I also understand that by submitting this form, I will be receiving emails, texts or calls about this study. For more information, please refer to the Privacy Policy (https://www.nzcr.co.nz/privacy-policy/).